BCR-ABL uncouples canonical JAK2-STAT5 signaling in chronic myeloid leukemia
Published 2012 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
BCR-ABL uncouples canonical JAK2-STAT5 signaling in chronic myeloid leukemia
Authors
Keywords
-
Journal
Nature Chemical Biology
Volume 8, Issue 3, Pages 285-293
Publisher
Springer Nature
Online
2012-01-30
DOI
10.1038/nchembio.775
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- High STAT5 levels mediate imatinib resistance and indicate disease progression in chronic myeloid leukemia
- (2011) W. Warsch et al. BLOOD
- The STAT5 inhibitor pimozide decreases survival of chronic myelogenous leukemia cells resistant to kinase inhibitors
- (2011) E. A. Nelson et al. BLOOD
- Preclinical characterization of the selective JAK1/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms
- (2010) A. Quintas-Cardama et al. BLOOD
- Phosphotyrosine Signaling: Evolving a New Cellular Communication System
- (2010) Wendell A. Lim et al. CELL
- Stat5 is indispensable for the maintenance ofbcr/abl-positive leukaemia
- (2010) Andrea Hoelbl et al. EMBO Molecular Medicine
- JAK inhibitor therapy for myelofibrosis: critical assessment of value and limitations
- (2010) A Pardanani et al. LEUKEMIA
- Janus kinase 2 regulates Bcr–Abl signaling in chronic myeloid leukemia
- (2010) A Samanta et al. LEUKEMIA
- The proximal signaling network of the BCR-ABL1 oncogene shows a modular organization
- (2010) B Titz et al. ONCOGENE
- Epidemiologic study on survival of chronic myeloid leukemia and Ph+ acute lymphoblastic leukemia patients with BCR-ABL T315I mutation
- (2009) F. E. Nicolini et al. BLOOD
- The JAK2 Inhibitor AZD1480 Potently Blocks Stat3 Signaling and Oncogenesis in Solid Tumors
- (2009) Michael Hedvat et al. CANCER CELL
- Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia
- (2009) A Hochhaus et al. LEUKEMIA
- Jak2 inhibition deactivates Lyn kinase through the SET–PP2A–SHP1 pathway, causing apoptosis in drug-resistant cells from chronic myelogenous leukemia patients
- (2009) A K Samanta et al. ONCOGENE
- Charting the molecular network of the drug target Bcr-Abl
- (2009) M. Brehme et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Translation of the Philadelphia chromosome into therapy for CML
- (2008) B. J. Druker BLOOD
- Selective Inhibition of JAK2-Driven Erythroid Differentiation of Polycythemia Vera Progenitors
- (2008) Ifat Geron et al. CANCER CELL
- Efficacy of TG101348, a Selective JAK2 Inhibitor, in Treatment of a Murine Model of JAK2V617F-Induced Polycythemia Vera
- (2008) Gerlinde Wernig et al. CANCER CELL
- Genetic complexity of myeloproliferative neoplasms
- (2008) R Kralovics LEUKEMIA
- Global target profile of the kinase inhibitor bosutinib in primary chronic myeloid leukemia cells
- (2008) L L Remsing Rix et al. LEUKEMIA
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now